Epitalon
Epithalon / AEDG (Ala-Glu-Asp-Gly)
Epitalon is a four-residue synthetic peptide, Ala-Glu-Asp-Gly. It is the most-discussed compound in the Khavinson catalog and the one most often described using evidence that belongs to something else. The human trial record everybody cites is on Epithalamin — the pineal extract — not on this tetrapeptide. This page keeps those apart, walks the sequence argument end to end, and says what a result would have to look like to settle it.
Epitalon quick facts
| Reported research dosing (Injectable) | 2mg-5mg |
| Route | Subq |
| Cycle length | 10-20 Days |
| Frequency | 1x Daily PM |
| Half-life | Short (pineal accumulation) |
| Forms | Injectable, Nasal, Oral |
| Evidence level | Russian human studies + animal |
| Other forms available | Nasal, Oral — dosed differently |
Short courses, 1–2x a year — that's the studied pattern. Don't run it year-round.
How Epitalon works — what 4 residues can and cannot do
Epitalon is Ala-Glu-Asp-Gly — a tetrapeptide, molecular weight 390.4 g/mol, isoelectric point 3.55, net charge about -2.1 at blood pH. Those four numbers are computed from the sequence, not quoted from a vendor.
Four residues, and the claim attached to them is that they select a specific stretch of DNA. Start with what that would require. A zinc finger uses roughly 30 amino acids to read three base pairs, and a protein needs three of those fingers in a row — around 90 residues — to recognize nine or ten bases with any confidence. Ala-Glu-Asp-Gly has four side chains, no fold, no hydrophobic core, and nothing to hold a shape with.
The arithmetic nobody in this market does. Suppose the tetrapeptide really did read a four-base site. A given four- base sequence turns up about once every 44 = 256 base pairs of random DNA. The human genome is roughly 3.1 billion base pairs, so that site occurs around twelve million times. Even a nine-base site — the length a three-finger protein reads — occurs tens of thousands of times. This is why real transcription factors do not work by sequence alone: they need cooperative binding, chromatin accessibility and partner proteins to land where they land. A free tetrapeptide has none of those. Sequence specificity in the sense the marketing means it is not available at this size.
So what is Khavinson's group actually proposing? Not transcription-factor mimicry. Their published model is that these peptides sit in the DNA groove, contact the backbone and the exposed edges of base pairs, and locally destabilize pairing or interfere at methylation sites — a chemical nudge to chromatin rather than a read-out of a promoter address. In their own systematic docking study the effect they could demonstrate computationally was a preference, scored in energy units, not a measured binding constant. That distinction is the whole ballgame and it is missing from every other page about this compound.
And here is the specific problem for Epitalon. At blood pH the molecule carries a net charge near −2, because two of its four residues are acidic. DNA's phosphate backbone is polyanionic. The proposed partner and the proposed ligand repel each other. That does not make contact impossible — groove interactions are local and the acidic side chains are exactly the ones proposed to destabilize base pairing — but it is a genuine energetic cost, and the popular version of this story never mentions it.
PubChem CID 219042 lists Epitalon as C14H22N4O9,/mol. peptide_chem recomputes exactly that formula from Ala-Glu-Asp-Gly, so the sequence and the registered compound agree.
What the primary literature on Epitalon actually says
Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice
Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NY, Semenchenko AV, Yashin AI · Biogerontology 2003;4(4):193–202
The most-cited animal study, and it is more interesting than its reputation. 54 female SHR mice per group, subcutaneous on five consecutive days every month from three months of age until natural death, saline control. Mean life span did not change. Food consumption and body weight did not change. What did move: chromosome aberrations in bone-marrow cells fell 17.1% (P<0.05), the life span of the last 10% of survivors rose 13.3% (P<0.01), and maximum life span rose 12.3%. A maximum-lifespan effect with no mean-lifespan effect is a specific, unusual result — it is not the same claim as 'extends life'.
Peptide Regulation of Gene Expression: A Systematic Review
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR · Molecules 2021;26(22):7053 · PMID 34834147
The mechanism review from the originating group. AEDG is credited with regulating 98 genes, and specifically with acting on Clock, Csnk1e and Cry2 — the circadian machinery — and with restoring melatonin production. This is the sharpest version of the Epitalon hypothesis: not 'anti-aging', but a circadian-gene claim that names three genes and is therefore testable.
PubChem Compound Summary CID 219042 — Epitalon (C14H22N4O9,/mol)
National Center for Biotechnology Information · PubChem, NCBI
Identity, not efficacy. Worth citing because it is the one thing about this compound that is settled: it is a registered chemical entity with a formula that matches its stated sequence.
Why the Epitalon evidence is weak — and what it still showed
Almost every human result in this class comes from one school — Vladimir Khavinson's institute in St Petersburg and the groups around it. That means single-center data, collected by the people who developed the compound, rarely blinded, never pre-registered, and reported across enough endpoints that something was always going to move. Read anything below against that.
Specific to Epitalon. The specific problem with Epitalon is not trial quality, it is attribution. Khavinson & Morozov's 266-subject human series — the source of every 'peptides prolong human life' headline — used Epithalamin, a pineal extract, and Thymalin, a thymus extract. Epitalon is a synthetic tetrapeptide. An extract and a four-residue peptide are not the same product, and a result on one is not evidence about the other. Read the trials against Epitalon and the honest count of human outcome trials is zero.
What the data does support. The Anisimov 2003 mouse study is a real experiment with a saline control and 54 animals per group, run to natural death. It reported chromosome aberrations in bone marrow down 17.1% (P<0.05), the last decile of survivors living 13.3% longer (P<0.01), maximum lifespan up 12.3%, and leukemia inhibited 6.0-fold — with mean lifespan unchanged and total tumor incidence unchanged. That is a specific and unusual signature: a tail effect without a mean effect. It is compatible with reduced late-life genomic damage in a mouse. It is not evidence of a lifespan effect in a human, and the paper does not claim one.
Where the case is strongest. Not longevity — circadian biology. The mechanism review credits Ala-Glu-Asp-Gly with acting on Clock, Csnk1e and Cry2 in leukocytes and blood lymphocytes, and with restoring the melatonin-forming function of the pineal gland. Three named genes and one hormone is a far sharper hypothesis than “anti-ageing”, and it is the version of the Epitalon claim that could actually be tested in a week.
What is actually measured, and what is not. Measured: 54 mice per group over a full lifespan; chromosome aberrations down 17.1% at P<0.05; maximum lifespan up 12.3%; molecular formula C14H22N4O9, confirmed against a registered chemical entity. Not measured, in any species: plasma half-life, clearance, oral bioavailability, nuclear uptake, and any binding constant against DNA. Not measured in humans: anything at all.
Not proven is not the same as disproven. Everything above says the evidence is weak. None of it says the compound does nothing. There is no adequately powered trial that ran and came back null, because outside Russia there is essentially no trial at all — this class is unfunded, not failed. A reader who leaves thinking “disproven” has learned something false, and so has one who leaves thinking “proven”.
Epitalon pharmacokinetics — how much of it actually gets in
What degrades it. Three peptide bonds, no disulfide, no ring, no terminal cap. Serum and tissue aminopeptidases cleave precisely this bond type, and there is no structural feature here to slow them down. Nobody has published a measured plasma half-life for Ala-Glu-Asp-Gly in a human. This Vault lists it as “Short (pineal accumulation)”, and the accumulation half of that phrase has no human pharmacokinetic study behind it — it comes from rodent tissue-distribution work.
The transporter question, answered properly. The case for swallowing any peptide in this family rests on PEPT1, the proton-coupled transporter on the brush-border membrane of the small intestine. The review from this same research group describes PEPT1's substrate range as “basically all di- and tripeptides”. Epitalon has four residues. Its sibling transporter PEPT2 does take tetrapeptides — “di-, tri- and tetrapeptides (preferably dipeptides)” — but PEPT2 sits mainly in the kidney proximal tubule, not in the gut wall. So the single named mechanism that makes an oral short peptide arguable is the one mechanism that does not clearly cover this molecule.
Bound the exposure rather than leaving it blank. A subcutaneous injection is 100% bioavailable by definition; it skips the gut wall and hepatic first-pass entirely. Epitalon is sold in injectable, nasal and oral form at reference amounts that do not differ by anything like the factor those routes differ by. For a swallowed capsule to deliver the systemic exposure of an injection, an intact tetrapeptide would have to survive gastric acid, pancreatic proteases, the brush-border peptidase layer and then the cytosolic peptidases inside the enterocyte. Each of those is a well-characterized barrier. The fraction that gets through has never been measured for this compound, and stating that bound honestly is more useful than the word “Short” on its own.
The ratio the catalog itself implies. Across this class, the oral products carry a median of roughly 29x more material per day than the injectable ones. Nobody arrived at that by measuring absorption — no oral bioavailability figure has been published for any compound in this family — but the gap is the vendors' own implicit answer to the question: swallowing it is assumed to deliver a small fraction of what an injection delivers, and an injection is fully bioavailable by definition. Treat that as a bound on the plausible exposure, not as a measurement, because a measurement is exactly what is missing.
What would have to be true for Epitalon to work
What would have to be true. Four things, in order. The tetrapeptide would have to survive long enough to reach a target tissue; cross a plasma membrane it is too charged to diffuse through; enter the nucleus by a route nobody has described; and shift transcription enough to move something measurable in blood or behavior. Step one has a candidate mechanism. Steps two and three have none. Step four has never been shown in a human for this molecule.
The circadian claim is the one worth attacking, because it is cheap to test and it names its own genes.
- Prediction 1 — dim light melatonin onset. should shift earlier, or nocturnal 6-sulfatoxymelatonin should rise, within one 10–20 day course. If a circadian-gene mechanism is real, this is where it shows first and cheapest. If DLMO does not move in a group of poor sleepers, the Clock/Cry2 story is not operating at the doses people use.
- Prediction 2 — telomerase activity. should be measurable in a peripheral tissue, not only in cultured cells, within a course. Every telomerase claim for this compound traces to cell culture. A single leukocyte telomerase assay in treated humans would move this from theoretical to correlative overnight. Nobody has published one.
- Prediction 3 — IGF-1 (Insulin-like Growth Factor 1). should NOT move, over any course length. This is a negative prediction and it matters. If IGF-1 climbs on a bioregulator, something other than the stated mechanism is happening — most likely the vial does not contain what the label says.
Run these before and after, not after alone. A single post-course number tells you what your body is doing, not what Epitalon did to it — and that difference is the entire point of testing.
Epitalon versus the alternatives
Epitalon versus Endoluten — the comparison this catalog exists to avoid. Endoluten is the pineal extract. Epitalon is a synthetic tetrapeptide. The entire human outcome record everyone cites for “Epitalon” — the 266-subject elderly series — was run on Epithalamin, the extract, not on this molecule. The argument for the extract is that it works through short peptides like this one; the argument for the peptide is that it is a defined, verifiable chemical. Both cannot be the stronger buy. Nobody has ever run them head to head, and until somebody does, choosing between them is choosing between evidence attached to an unverifiable product and verifiability attached to an unevidenced one.
And against the credible alternative: there isn't one. No approved drug claims to do what Epitalon claims to do. That cuts both ways — there is nothing with better data to point you at, and there is also nothing establishing that the target is real. If the goal is sleep or circadian timing specifically, light exposure timing and melatonin have actual human trial data and cost nothing.
What you are actually buying when you buy Epitalon
This is the one compound in the family whose identity is settled. Epitalon is registered as PubChem CID 219042 with molecular formula C14H22N4O9, and this repo recomputes exactly that formula from Ala-Glu-Asp-Gly — the registered compound and the stated sequence agree. So a certificate of analysis here is worth something concrete: mass spectrometry can confirm the mass outright and HPLC can put a number on purity. Ask for both. The mass is the one claim on the vial a laboratory can falsify, and it is the check most buyers never make.
A certificate of analysis on a defined tetrapeptide is meaningful: mass spectrometry can confirm/mol and HPLC can put a number on purity. Ask for both, and check the mass — it is the one claim on the vial that a lab can falsify.
Where to get Epitalon
Epitalon is sold in 3 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.
Epitalon reconstitution calculator
Research reconstitution calculator
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Epitalon
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- The Khavinson group published multi-year follow-up in elderly Russian cohorts reporting reduced mortality and normalized melatonin rhythm. These are the strongest human claims made for any bioregulator and the hardest to verify — largely single-group, rarely blinded, and never independently replicated outside Russia.
- Modern use is short annual courses, which is the protocol those studies used rather than something invented later.
🧪 Theoretical / extrapolated
- A tetrapeptide (Ala-Glu-Asp-Gly) proposed to act on the pineal gland and to induce telomerase. Cell-culture work shows extended replicative lifespan in human fibroblasts, and rodent work shows lifespan extension.
- Telomerase induction is the mechanism and also the open question. Lengthening telomeres in somatic cells is exactly what a cancer cell does, and nobody has run the long human study that would settle whether that matters here.
What that tier rests on here. The tier above is carried almost entirely by rodent work and cell culture. The human series everyone cites for “Epitalon” studied Epithalamin, the pineal extract — a different product. Read the correlative tier as animal data, not as human data.
How to read the Soviet clinical series →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
Cell, rodent, human — and where it stops
In cells, and this is the paragraph that separates Epitalon from everything else in this catalog. Al-Dulaimi 2025 treated four human cell types — the breast cancer lines 21NT and BT474, plus normal epithelial cells and normal fibroblasts — then pulled DNA, RNA and protein and read them by qPCR and immunofluorescence. In the normal cells telomere length rose in a dose-dependent way, and it rose through hTERT mRNA and telomerase enzyme activity. In the cancer lines telomeres also lengthened, but by a different route: ALT, alternative lengthening of telomeres, which was raised only slightly in the normal cells. Two mechanisms, split by cell type, in one experiment.
Three more labs, three more systems, none of them in St Petersburg. Yue 2022 used mouse oocytes held past ovulation and reported protection against post-ovulatory aging damage. Ullah 2025 took it to bovine oocytes and reported higher maturation rates and better post-thaw embryo development. Gatta 2025 ran it in a cell model of diabetic retinopathy and reported faster wound closure. Mouse, cow and human cells, published 2022 to 2025, in Aging, Life Sciences, Stem Cell Reviews and Reports and Biogerontology — journals with no connection to the people who invented the molecule. One caveat belongs here and not in a footnote: the Biogerontology paper carries a published correction, Al-Dulaimi 2025, and a reader checking this page's strongest citation should open both.
And here is exactly where it stops. Every result above is in vitro. The originating group's own contribution is a mechanism paper on gene expression during neurogenesis Khavinson 2020 and a rodent lifespan series; the only human measurement anyone has published with this tetrapeptide in it is a serum enzyme assay Kost 2003. There is no human trial of Epitalon with a telomere endpoint. Not a small one, not a bad one — none. The human record that gets quoted for Epitalon belongs to Epithalamin, the pineal extract, which is a different product.
What nobody has tested yet
Leukocyte telomere length before and after. The assay is commercially available, it needs one tube of blood, and it measures the exact quantity four cell papers say this molecule moves. Nobody has published a single before-and-after pair in a person. A dozen people running it around a course would produce more human evidence for Epitalon than currently exists anywhere.
The ALT result is the experiment nobody wants to run, which is why it is the one worth naming. Al-Dulaimi 2025 did not find a molecule that lengthens telomeres only in healthy cells. It found one that lengthened them in two breast cancer lines through a pathway cancers use to become immortal without telomerase. Whether that happens in a living animal with an occult tumor has never been tested in any species, and it is the question a longevity peptide with a telomerase mechanism most needs answered.
Extrapolation, labeled as such. If the effect really runs through hTERT transcription, three things should follow that nobody has looked for: it should be time-dependent as well as concentration-dependent, it should disappear in cells with hTERT silenced, and it should be invisible in cell types that never express telomerase at all. None of those three controls appears in the published record. They are ordinary molecular biology, and they would settle whether the mechanism on the label is the mechanism.
Sources read for this page
- Al-Dulaimi S. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025 · PMID 40908429
- Al-Dulaimi S. Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025 · PMID 41240216
- Yue X. Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro. Aging (Albany NY) 2022 · PMID 35413689
- Ullah S. Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development. Life Sciences 2025 · PMID 39788414
- Gatta M. The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. Stem Cell Reviews and Reports 2025 · PMID 40493162
- Khavinson V. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules 2020 · PMID 32019204
- Kost NV, Sokolov OIu, Gabaeva MV, Zolotarev IuA, Malinin VV, Khavinson VKh. Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum. Izvestiia Akademii Nauk Seriia Biologicheskaia 2003 [Russian] · PMID 12942748
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
Epitalon — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Epitalon — safety specifics for this compound
Specific to Epitalon: the compound is acidic and lyophilized, and the reconstituted solution is the part that goes wrong in practice — short peptides in solution degrade, and there is no preservative in a bacteriostatic-free reconstitution. The honest unknown is different from the class boilerplate: because the proposed mechanism is transcriptional and circadian, the plausible adverse effect is not toxicity but timing — sleep phase shifting in the wrong direction. Nobody has studied that, and it would not show up on a standard panel.
Evening, through a short course
The pineal and CNS bioregulators are dosed at night because the tissue they target runs on a nocturnal rhythm. For the others the time of day is not the variable that matters — the course-and-gap structure is, and getting that right outweighs any hour of the clock.
From half-life and route, not a dosing trial.
Epitalon — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Epitalon moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
Everything on this page, in an order
This one is free and stays free. What Skool adds is the rest of the shelf — 278 compounds and 371 supplements with the protocol, the stack order and the bloodwork to run beside it.
Join Skool — $10/mo →Bloodwork to run alongside Epitalon
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| IGF-1 (Insulin-like Growth Factor 1) | Claimed to modulate the GH axis; this is where that would show |
| hs-CRP (High-Sensitivity C-Reactive Protein) | Inflammation baseline |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Epitalon — frequently asked questions
What is the amino acid sequence of Epitalon?
Epitalon is Ala-Glu-Asp-Gly — 4 residues, 390.4 g/mol, isoelectric point 3.55. Those figures are computed from the sequence rather than quoted.
Can a peptide that short really bind DNA?
Not the way a transcription factor does. A zinc finger needs about 30 residues to read three base pairs. When Khavinson's group docked all 400 dipeptides against DNA, the vast majority could not bind double-stranded DNA at all. The claim is a computational prediction supported by gene-expression readouts in cells, not a measured binding event.
Is there a human trial of Epitalon?
See the literature section above — the record is named study by study.
What should I measure if I run Epitalon?
Before and after, not after alone. The falsifiability section on this page names the specific markers, the direction each should move and the timescale — and says what a null result would rule out.
References & further reading
- Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NY, Semenchenko AV, Yashin AI — Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice · Biogerontology 2003;4(4):193–202
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR — Peptide Regulation of Gene Expression: A Systematic Review · Molecules 2021;26(22):7053 · PMID 34834147
- National Center for Biotechnology Information — PubChem Compound Summary CID 219042 — Epitalon (C14H22N4O9, 390.35 g/mol) · PubChem, NCBI
Epitalon inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Epitalon is used for
Epitalon appears under 4 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Epitalon is the rhythm arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.